40.81
-1.23(-2.93%)
Currency In USD
| Previous Close | 42.04 |
| Open | 42.19 |
| Day High | 42.24 |
| Day Low | 40.42 |
| 52-Week High | 44.8 |
| 52-Week Low | 8.24 |
| Volume | 754,402 |
| Average Volume | 1.63M |
| Market Cap | 2.71B |
| PE | -11.46 |
| EPS | -3.56 |
| Moving Average 50 Days | 33.06 |
| Moving Average 200 Days | 18.17 |
| Change | -1.23 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $2,213.12 as of October 24, 2025 at a share price of $40.81. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 1 year ago, it would be worth $3,000.74 as of October 24, 2025 at a share price of $40.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
GlobeNewswire Inc.
Oct 21, 2025 12:00 PM GMT
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN Trial of lorundrostat to be included in “Best of Journa
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
GlobeNewswire Inc.
Sep 30, 2025 12:00 PM GMT
~ Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~ RADNOR, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to tar
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
GlobeNewswire Inc.
Sep 05, 2025 1:00 PM GMT
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and par